Search

Displaying results 2601 - 2610 of 10000 in total
  1. Drug

    Cinaciguat

    go.drugbank.com/drugs/DB16126
    Investigational

    Cinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 ΜG/h) Given Intravenously to Patients

  2. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting … as major side effects.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 Substrates
  3. Drug

    Pancrelipase protease

    go.drugbank.com/drugs/DB11066
    ApprovedInvestigational

    [A32742, L2543] The pancrelipase mixture, including pancrelipase protease, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]

    Mixtures: Pancrease Mt 10, Creon 10 Minimicrospheres
  4. Drug

    Flurpiridaz F-18

    go.drugbank.com/drugs/DB18773
    Approved

    [A264519] Flurpiridaz F-18 is an analog of pyridaben, a mitochondrial complex 1 (MC-1) inhibitor.[L51659]

    Synonyms: 2-tert-butyl-4-chloro-5-((4-((2-(18f)fluoroethoxy)methyl)phenyl)methoxy)pyridazin-3(2h)-one, 2-tert-butyl-4-chloro-5-[[4-(2-(18F)fluoranylethoxymethyl)phenyl]methoxy]pyridazin-3-one
  5. Drug

    Nabiximols

    go.drugbank.com/drugs/DB14011
    Investigational

    In Canada, Sativex® has received a Notice of Compliance (NOC) for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis (MS) who have not responded … Sativex® has also received a Notice of Compliance with Conditions (NOC/c) for use as an adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis (MS

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  6. Drug

    Chloride ion

    go.drugbank.com/drugs/DB14547
    Investigational

    Mixtures: VAMIN 14 IV AMINOASIT SOLÜSYONU, 500 ML, POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 500 ML (PVC TORBA) SETLI
  7. Drug

    Elexacaftor

    go.drugbank.com/drugs/DB15444
    ApprovedInvestigational

    [A187373]-90%[A187361,A187355] of all CF patients. … [L9395] Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure and mechanism as compared to first generation correctors like tezacaftor.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Substrates
  8. Drug

    Stearic acid

    go.drugbank.com/drugs/DB03193
    Approved

    Stearic acid (IUPAC systematic name: octadecanoic acid) is one of the useful types of saturated fatty acids that comes from many animal and vegetable fats and oils. It is a waxy solid.

    Mixtures: Isa Knox Ageless Serum Makeup Base 10, O Hui Veil Fit Dual Foundation 10Synonyms: C18:0
  9. Drug

    Chlortetracycline

    go.drugbank.com/drugs/DB09093
    ApprovedVet approvedWithdrawn

    The organism was named _Streptomyces aureofaciens_ due to its gold-hued color. … It was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow.

    Mixtures: Aureocort 1 mg/g + 30 mg/g Salbe
  10. Drug

    Zoliflodacin

    go.drugbank.com/drugs/DB12817
    ApprovedInvestigational

    [A274938,L54748] It is indicated as a single-dose oral therapy for the treatment of uncomplicated urogenital gonorrhea.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates